Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trolnitrate is a small molecule organic nitrate with vasodilator activity. It is primarily used to prevent or ameliorate attacks of angina pectoris. The drug functions by acting as a smooth muscle depressant, similar to nitroglycerin, leading to the dilation of coronary vessels. Its mechanism involves the release of nitric oxide, which subsequently stimulates soluble guanylate cyclase, increasing cyclic GMP (cGMP) levels and ultimately resulting in the relaxation of vascular smooth muscles. This action improves oxygen supply to the myocardium and reduces cardiac workload. Trolnitrate has also been investigated for its protective effects against myocardial necrosis. It reached a maximum clinical trial phase of II for at least one investigational indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Trolnitrate.